Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedAug 29, 2026
DataAggregated Company Financials
Companies181
  • 7D1.6%
  • 3M10.4%
  • 1Y19.6%
  • YTD19.3%

In the last week, the Pharma industry is up 1.6%, with Laurus Labs leading the way, up 7.6%. In the same time, Pfizer was down 5.5%. This means that the industry has gained 20% over the past year. As for the next few years, earnings are expected to grow by 18% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 29 Aug 2026₹24.6t₹4.7t₹656.5b30x37.5x5.3x
Mon, 27 Jul 2026₹23.7t₹4.4t₹631.6b29.3x37.5x5.4x
Wed, 24 Jun 2026₹23.0t₹4.5t₹642.9b29.8x35.8x5.1x
Fri, 22 May 2026₹22.4t₹4.5t₹635.9b29.3x35.3x5x
Sun, 19 Apr 2026₹20.5t₹4.3t₹621.0b28x33x4.7x
Tue, 17 Mar 2026₹20.3t₹4.3t₹621.2b25.5x32.7x4.7x
Thu, 12 Feb 2026₹20.2t₹4.3t₹616.4b28.3x32.7x4.7x
Sat, 10 Jan 2026₹20.3t₹4.2t₹613.3b28.5x33.1x4.8x
Mon, 08 Dec 2025₹20.6t₹4.2t₹612.9b29x33.6x4.9x
Wed, 05 Nov 2025₹20.3t₹4.1t₹596.1b30.2x34.1x5x
Fri, 03 Oct 2025₹20.0t₹4.1t₹588.1b30.6x34.1x4.9x
Sun, 31 Aug 2025₹20.0t₹4.1t₹589.1b29.6x33.9x4.9x
Tue, 29 Jul 2025₹20.9t₹4.0t₹597.0b32.5x35x5.2x
Thu, 26 Jun 2025₹20.1t₹4.0t₹595.3b32.7x33.8x5.1x
Sat, 24 May 2025₹19.8t₹4.0t₹580.2b31.8x34x4.9x
Mon, 21 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Wed, 19 Mar 2025₹19.1t₹3.9t₹559.4b28.7x34.1x4.9x
Fri, 14 Feb 2025₹19.3t₹3.9t₹550.6b28.8x35.1x5x
Sun, 12 Jan 2025₹20.5t₹3.8t₹527.0b33.7x38.9x5.4x
Tue, 10 Dec 2024₹20.7t₹3.8t₹526.7b36.2x39.4x5.4x
Thu, 07 Nov 2024₹21.3t₹3.8t₹508.0b39.9x41.9x5.6x
Sat, 05 Oct 2024₹21.4t₹3.7t₹492.6b41.2x43.5x5.7x
Mon, 02 Sep 2024₹21.2t₹3.7t₹492.4b39.8x43x5.7x
Wed, 31 Jul 2024₹19.5t₹3.7t₹461.3b38.2x42.3x5.3x
Fri, 28 Jun 2024₹17.4t₹3.6t₹448.3b33.6x38.8x4.9x
Sun, 26 May 2024₹17.1t₹3.5t₹443.8b33.4x38.5x4.8x
Tue, 23 Apr 2024₹16.6t₹3.5t₹418.9b33.2x39.6x4.8x
Thu, 21 Mar 2024₹16.4t₹3.5t₹418.7b31.8x39.2x4.7x
Sat, 17 Feb 2024₹16.9t₹3.5t₹418.9b33.7x40.4x4.9x
Mon, 15 Jan 2024₹15.7t₹3.4t₹395.3b35.2x39.6x4.6x
Wed, 13 Dec 2023₹14.1t₹3.4t₹395.1b31.3x35.7x4.2x
Fri, 10 Nov 2023₹13.6t₹3.3t₹388.9b30.1x35.1x4.1x
Sun, 08 Oct 2023₹13.1t₹3.3t₹369.9b30.1x35.4x4x
Tue, 05 Sep 2023₹12.9t₹3.3t₹367.0b29.8x35x3.9x
Price to Earnings Ratio

35x


Total Market Cap: ₹12.9tTotal Earnings: ₹367.0bTotal Revenue: ₹3.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 21% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.099%
Healthcare2.05%
Pharma1.59%
Pharma1.59%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LAURUSLABS Laurus Labs₹1.94k7.6%
+₹73.8b		126.2%PE95.8x
ZYDUSLIFE Zydus Lifesciences₹1.19k6.3%
+₹70.8b		21.4%PE26.3x
500420 Torrent Pharmaceuticals₹5.04k3.2%
+₹58.8b		41.5%PE87.8x
GLENMARK Glenmark Pharmaceuticals₹2.52k8.5%
+₹55.6b		30.7%PE39.5x
SUNPHARMA Sun Pharmaceutical Industries₹1.92k0.9%
+₹42.2b		20.4%PE38.1x

Latest News

ZYDUSLIFE
₹1,191.00
Zydus Lifesciences
7D
6.3%
1Y
21.4%
Narrative Update • Aug 26

ZYDUSLIFE: COPD Launch And USFDA Outcomes Will Shape Balanced Outlook

Analysts have raised the Zydus Lifesciences price target from about ₹1,094 to roughly ₹1,196, citing updated assumptions that include slightly lower discount rates, modestly higher revenue growth and a higher future P/E multiple, partly offset by a somewhat lower profit margin outlook. What’s in the News for Zydus Lifesciences Zydus Lifesciences launched REVAHALE (Revefenacin), described as India’s first once daily nebulised Long Acting Muscarinic Antagonist for maintenance treatment of COPD, aimed at patients who need nebulised therapy and may struggle with handheld inhalers.
GLENMARK
₹2,515.00
Glenmark Pharmaceuticals
7D
8.5%
1Y
30.7%
500660
₹3,106.10
GlaxoSmithKline Pharmaceuticals
7D
7.1%
1Y
11.6%
530549
₹904.25
Shilpa Medicare
7D
11.0%
1Y
113.7%
Narrative Update • Aug 19

530549: Dividend Decision And Office Shift Will Shape Balanced Future Outlook

Analysts have lifted their fair value estimate for Shilpa Medicare from ₹748 to ₹870, citing updated assumptions for slightly higher revenue growth, profit margins, and a marginally lower future P/E multiple and discount rate. What's in the News for Shilpa Medicare Board meeting scheduled on 5 Aug 2026 to consider and approve unaudited financial results for the quarter ended 30 Jun 2026.
CONCORDBIO
₹1,481.10
Concord Biotech
7D
-5.7%
1Y
-11.9%
Narrative Update • Aug 18

CONCORDBIO: Higher Future P/E Will Likely Restrain Returns From Current Levels

Analysts have raised their fair value estimate for Concord Biotech from ₹1,020 to ₹1,268, citing updated assumptions for revenue growth, profit margins and future P/E levels as key drivers of the higher price target. What’s in the News for Concord Biotech A board meeting is scheduled on May 29, 2026 to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, consider a final equity dividend recommendation, review director appointments, and address other business matters.
500257
₹2,175.00
Lupin
7D
-0.8%
1Y
14.9%
ALKEM
₹5,355.00
Alkem Laboratories
7D
-0.8%
1Y
1.0%
Narrative Update • Aug 17

ALKEM: Elevated P/E Will Persist Despite New Diabetes Drug Rollout

Analysts have raised their price target for Alkem Laboratories from ₹4,557.94 to ₹4,724.64, based on updated assumptions for the discount rate, revenue growth, profit margin and forward P/E multiples. What's in the News Alkem Laboratories has a board meeting scheduled on 14 August 2026 to consider and approve standalone and consolidated unaudited financial results for the quarter ended 30 June 2026.
500420
₹5,035.00
Torrent Pharmaceuticals
7D
3.2%
1Y
41.5%
Narrative Update • Aug 14

500420: Dividend Support And Higher Assumptions Will Drive A Stronger Outlook

Analysts have raised their price target for Torrent Pharmaceuticals from ₹5,084 to ₹5,387, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple in their refreshed models. What’s in the News for Torrent Pharmaceuticals Torrent Pharmaceuticals has scheduled a board meeting on Jul 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, along with other business matters.
AJANTPHARM
₹3,557.00
Ajanta Pharma
7D
-2.3%
1Y
43.6%
Narrative Update • Aug 14

AJANTPHARM: Rich Earnings Multiple And Recall Risk Will Restrain Upside

Ajanta Pharma's analyst price target has been revised to ₹3,149 from ₹2,701, with analysts citing updated fair value and P/E assumptions, as well as modest adjustments to the discount rate, revenue growth and profit margin inputs as the main factors behind this change. What's in the News for Ajanta Pharma Ajanta Pharma has scheduled a board meeting on July 30, 2026, to consider and approve unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.
LAURUSLABS
₹1,938.50
Laurus Labs
7D
7.6%
1Y
126.2%
Narrative Update • Aug 14

LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples

The Laurus Labs analyst price target has been updated from ₹1,044.00 to about ₹1,486.29. This change is supported by analyst assumptions that reflect higher revenue growth, stronger profit margins and a modestly higher future P/E, while keeping the discount rate broadly similar.
506820
₹7,106.25
AstraZeneca Pharma India
7D
-4.1%
1Y
-16.1%
532482
₹836.95
Granules India
7D
-2.5%
1Y
70.1%
SUNPHARMA
₹1,920.00
Sun Pharmaceutical Industries
7D
0.9%
1Y
20.4%
Analysis Article • Aug 05

Results: Sun Pharmaceutical Industries Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) recently reported its quarterly numbers. Sun...
CIPLA
₹1,423.50
Cipla
7D
-0.6%
1Y
-10.4%
PFIZER
₹4,703.80
Pfizer
7D
-5.5%
1Y
-8.8%
WOCKPHARMA
₹1,977.10
Wockhardt
7D
4.8%
1Y
38.5%